1,038 Shares in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Bought by S Bank Fund Management Ltd

Key Points

• S Bank Fund Management Ltd has made a significant new investment in Regeneron Pharmaceuticals, acquiring 1,038 shares valued at approximately $658,000 in the first quarter of the year.
• Regeneron Pharmaceuticals reported strong financial performance with $12.89 earnings per share (EPS), significantly exceeding analysts' expectations of $8.43, while also achieving a 3.6% year-over-year revenue growth.
• The company declared a quarterly dividend of $0.88 per share, translating to an annualized dividend yield of 0.6%, with a dividend payout ratio of 8.87%.

S Bank Fund Management Ltd bought a new stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm bought 1,038 shares of the biopharmaceutical company's stock, valued at approximately $658,000.

A number of other institutional investors and hedge funds also recently made changes to their positions in REGN. Capital International Investors lifted its stake in shares of Regeneron Pharmaceuticals by 41.6% in the 4th quarter. Capital International Investors now owns 4,736,929 shares of the biopharmaceutical company's stock valued at $3,373,859,000 after purchasing an additional 1,390,534 shares during the period. GAMMA Investing LLC lifted its stake in shares of Regeneron Pharmaceuticals by 89,825.0% in the 1st quarter. GAMMA Investing LLC now owns 815,620 shares of the biopharmaceutical company's stock valued at $517,291,000 after purchasing an additional 814,713 shares during the period. Price T Rowe Associates Inc. MD lifted its stake in shares of Regeneron Pharmaceuticals by 63.5% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 2,085,447 shares of the biopharmaceutical company's stock valued at $1,485,527,000 after purchasing an additional 810,144 shares during the period. Nuveen LLC purchased a new position in shares of Regeneron Pharmaceuticals in the 1st quarter valued at approximately $343,764,000. Finally, Pacer Advisors Inc. lifted its stake in shares of Regeneron Pharmaceuticals by 2,296.9% in the 1st quarter. Pacer Advisors Inc. now owns 407,370 shares of the biopharmaceutical company's stock valued at $258,366,000 after purchasing an additional 390,374 shares during the period. Hedge funds and other institutional investors own 83.31% of the company's stock.

Regeneron Pharmaceuticals Stock Performance

Shares of REGN traded up $4.42 during trading hours on Thursday, hitting $565.97. The stock had a trading volume of 975,056 shares, compared to its average volume of 986,507. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.60 and a quick ratio of 3.72. Regeneron Pharmaceuticals, Inc. has a 12 month low of $476.49 and a 12 month high of $1,211.20. The firm has a market capitalization of $59.99 billion, a PE ratio of 14.26, a PEG ratio of 1.90 and a beta of 0.33. The stock has a fifty day moving average price of $542.46 and a 200 day moving average price of $596.26.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last issued its quarterly earnings data on Friday, August 1st. The biopharmaceutical company reported $12.89 EPS for the quarter, topping the consensus estimate of $8.43 by $4.46. Regeneron Pharmaceuticals had a return on equity of 15.06% and a net margin of 31.37%. The company had revenue of $3,675,600 billion during the quarter, compared to analyst estimates of $3.30 billion. During the same quarter in the previous year, the company posted $11.56 earnings per share. Regeneron Pharmaceuticals's revenue was up 3.6% compared to the same quarter last year. Analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current year.

Regeneron Pharmaceuticals Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, September 3rd. Investors of record on Monday, August 18th will be issued a $0.88 dividend. The ex-dividend date of this dividend is Monday, August 18th. This represents a $3.52 annualized dividend and a dividend yield of 0.6%. Regeneron Pharmaceuticals's payout ratio is presently 8.87%.

Analyst Upgrades and Downgrades

A number of research analysts have issued reports on REGN shares. Canaccord Genuity Group reiterated a "buy" rating and set a $850.00 price objective on shares of Regeneron Pharmaceuticals in a research note on Wednesday, July 23rd. UBS Group reiterated a "neutral" rating on shares of Regeneron Pharmaceuticals in a research note on Friday, August 1st. Cantor Fitzgerald started coverage on Regeneron Pharmaceuticals in a research note on Tuesday, April 22nd. They set an "overweight" rating and a $695.00 price objective for the company. Robert W. Baird lowered their price objective on Regeneron Pharmaceuticals from $759.00 to $652.00 and set a "neutral" rating for the company in a research note on Friday, April 25th. Finally, Citigroup reiterated a "buy" rating and set a $650.00 price objective on shares of Regeneron Pharmaceuticals in a research note on Friday, August 1st. One investment analyst has rated the stock with a sell rating, seven have given a hold rating, seventeen have assigned a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average target price of $838.00.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.